ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance

Key Takeaways ADMA reported Q4 revenues of $139.2M, up 18%, with adjusted EPS rising to 21 cents.Asceniv sales jumped 51% in 2025 to $363M, fueling total revenue growth of 20%.ADMA guides 2026 revenues above $635M as yield-enhanced output boosts margins.ADMA Biologics (ADMA) reported fourth-quarter 2025 adjusted earnings per share (EPS) of 21 cents, (excluding stock-based compensation modifications, yield enhancement expense up, voluntary withdrawal and product replacements and non-recurring professional fe ...